BACKGROUND: Global genomic hypomethylation is a common epigenetic event in cancer that mostly results from hypomethylation of repetitive DNA elements. Case-control studies have associated blood leukocyte DNA hypomethylation with several cancers. Because samples in case-control studies are collected after disease development, whether DNA hypomethylation is causal or just associated with cancer development is still unclear. METHODS: In 722 elderly subjects from the Normative Aging Study cohort, we examined whether DNA methylation in repetitive elements (Alu, LINE-1) was associated with cancer incidence (30 new cases, median follow-up: 89 months), prevalence (205 baseline cases), and mortality (28 deaths, median follow-up: 85 months). DNA methylation was measured by bisulfite pyrosequencing. RESULTS: Individuals with low LINE-1 methylation (<median) had a 3.0-fold (95%CI 1.3-6.9) increased incidence of all cancers combined. LINE-1 and Alu methylation were not significantly associated with cancer prevalence at baseline (all cancers combined). However, individuals with low LINE-1 methylation (<median) had a 3.2-fold (95% CI 1.4-7.5) higher prevalence of lung cancer. Individuals with low LINE-1 or Alu methylation (<median) had increased cancer mortality (HR = 3.2, 95%CI 1.3-7.9 for LINE-1; HR = 2.5, 95%CI 1.1-5.8 for Alu). CONCLUSION: These findings suggest that individuals with lower repetitive element methylation are at high risk of developing and dying from cancer.
BACKGROUND: Global genomic hypomethylation is a common epigenetic event in cancer that mostly results from hypomethylation of repetitive DNA elements. Case-control studies have associated blood leukocyte DNA hypomethylation with several cancers. Because samples in case-control studies are collected after disease development, whether DNA hypomethylation is causal or just associated with cancer development is still unclear. METHODS: In 722 elderly subjects from the Normative Aging Study cohort, we examined whether DNA methylation in repetitive elements (Alu, LINE-1) was associated with cancer incidence (30 new cases, median follow-up: 89 months), prevalence (205 baseline cases), and mortality (28 deaths, median follow-up: 85 months). DNA methylation was measured by bisulfite pyrosequencing. RESULTS: Individuals with low LINE-1 methylation (<median) had a 3.0-fold (95%CI 1.3-6.9) increased incidence of all cancers combined. LINE-1 and Alu methylation were not significantly associated with cancer prevalence at baseline (all cancers combined). However, individuals with low LINE-1 methylation (<median) had a 3.2-fold (95% CI 1.4-7.5) higher prevalence of lung cancer. Individuals with low LINE-1 or Alu methylation (<median) had increased cancer mortality (HR = 3.2, 95%CI 1.3-7.9 for LINE-1; HR = 2.5, 95%CI 1.1-5.8 for Alu). CONCLUSION: These findings suggest that individuals with lower repetitive element methylation are at high risk of developing and dying from cancer.
Authors: Thomas Hillemacher; Helge Frieling; Susanna Moskau; Marc A N Muschler; Alexander Semmler; Johannes Kornhuber; Thomas Klockgether; Stefan Bleich; Michael Linnebank Journal: Eur Neuropsychopharmacol Date: 2008-01-31 Impact factor: 4.600
Authors: Hans T Bjornsson; Martin I Sigurdsson; M Daniele Fallin; Rafael A Irizarry; Thor Aspelund; Hengmi Cui; Wenqiang Yu; Michael A Rongione; Tomas J Ekström; Tamara B Harris; Lenore J Launer; Gudny Eiriksdottir; Mark F Leppert; Carmen Sapienza; Vilmundur Gudnason; Andrew P Feinberg Journal: JAMA Date: 2008-06-25 Impact factor: 56.272
Authors: C Sloane Furniss; Carmen J Marsit; E Andres Houseman; Karen Eddy; Karl T Kelsey Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Martin Widschwendter; Sophia Apostolidou; Elke Raum; Dietrich Rothenbacher; Heidi Fiegl; Usha Menon; Christa Stegmaier; Ian J Jacobs; Hermann Brenner Journal: PLoS One Date: 2008-07-16 Impact factor: 3.240
Authors: Heather H Burris; Sheryl L Rifas-Shiman; Andrea Baccarelli; Letizia Tarantini; Caroline E Boeke; Ken Kleinman; Augusto A Litonjua; Janet W Rich-Edwards; Matthew W Gillman Journal: J Dev Orig Health Dis Date: 2012-06 Impact factor: 2.401
Authors: Sara Karami; Gabriella Andreotti; Linda M Liao; Ruth M Pfeiffer; Stephanie J Weinstein; Mark P Purdue; Jonathan N Hofmann; Demetrius Albanes; Satu Mannisto; Lee E Moore Journal: Epigenetics Date: 2015-02-03 Impact factor: 4.528
Authors: Rhiannon J Walters; Elizabeth J Williamson; Dallas R English; Joanne P Young; Christophe Rosty; Mark Clendenning; Michael D Walsh; Susan Parry; Dennis J Ahnen; John A Baron; Aung Ko Win; Graham G Giles; John L Hopper; Mark A Jenkins; Daniel D Buchanan Journal: Epigenetics Date: 2013-06-17 Impact factor: 4.528
Authors: Maria Keller; Susan Kralisch; Kerstin Rohde; Dorit Schleinitz; Arne Dietrich; Michael R Schön; Daniel Gärtner; Tobias Lohmann; Miriam Dreßler; Anke Tönjes; Michael Stumvoll; Peter Kovacs; Mathias Fasshauer; Matthias Blüher; Yvonne Böttcher Journal: Diabetologia Date: 2014-08-22 Impact factor: 10.122
Authors: Marco Peluso; Valentina Bollati; Armelle Munnia; Petcharin Srivatanakul; Adisorn Jedpiyawongse; Suleeporn Sangrajrang; Sara Piro; Marcello Ceppi; Pier Alberto Bertazzi; Paolo Boffetta; Andrea A Baccarelli Journal: Int J Epidemiol Date: 2012-10-13 Impact factor: 7.196
Authors: Kathryn Hughes Barry; Lee E Moore; Linda M Liao; Wen-Yi Huang; Gabriella Andreotti; Matthew Poulin; Sonja I Berndt Journal: Prostate Date: 2015-08-07 Impact factor: 4.104